Archive

Category Archives for "公开发售"

Sichenzia Ross Ference LLP代表Beyond Air,Inc.进行1150万美元的承销普通股和并行私募的公开发行

beyond air logo

新闻稿-纽约州,纽约-2019年12月12日-Sichenzia Ross Ference LLP今天宣布代表Beyond Air,Inc.(NASDAQ:XAIR),一家专注于开发可吸入一氧化氮(NO)的临床阶段医疗器械和生物制药公司。为治疗严重的呼吸道疾病,以每股3.66美元的价格成功完成了承销的公开发行和并发私募的约1150万美元的Beyond Air普通股。公开发行是根据向证券交易委员会提交的有效货架注册声明进行的。私募股份不会被注册。

continue reading >>

Sichenzia Ross Ference LLP代表Aegis Capital以450万美元公开发售Avinger,Inc。普通股

avinger logo

新闻稿 – 纽约州纽约市 –  2019年8月26日 – Sichenzia Ross Ference LLP今天宣布,它已代表Aegis Capital Corp.作为公开发行股票的唯一账簿管理人,共同出售3,813,559股Avinger,Inc。(纳斯达克股票代码:AVGR)股票股票,每股1.18美元,总收益约为450万美元。 Avinger是外周动脉疾病创新治疗的领先开发商

continue reading >>

Sichenzia Ross Ference Kesner LLP Represents Aegis Capital Corp. in $6 Million Public Offering of Units of Precipio, Inc.

precipio diagnostics

Press Release – New York, NY – August 23rd, 2017 –  Sichenzia Ross Ference Kesner LLP announced today that it has represented Aegis Capital Corp. as sole book running manager in the underwritten public offering of Units of Precipio, Inc. (NASDAQ: PRPO). Each Unit is comprised of 1 share of Series B Preferred Stock which is convertible into 400 shares of common stock at a price of $2.50 per share and one warrant to purchase 400 shares of common stock at $3.00 per share.   Precipio provides diagnostic information to physicians and there patients worldwide.  The Sichenzia Ross Ference Kesner LLP team was led by partner Tom Rose and counsel Jeff Cahlon.

思成律师事务所成功代理2000万美元证券公开发行

china internet nationwide financial services

新闻稿纽约市,纽约州 – 2017731 在全国享誉盛名的证券法与公司法律师事务所,Sichenzia Ross Ference Kesner LLP(思成律师事务所),今日宣布其成功代理China Internet Nationwide Financial Services Inc.NASDAQCIFS)进行首次公开发行China Internet Nationwide Financial Services Inc.是一家向需要金融支持的广大中国中小企业提供金融咨询服务的公司。本次发行共计2,023,146股普通股,每股股价10.00美元共募集20,231,460美元 公司股票预计将于201788日在纳斯达克全球市场开始交易,交易代码为CIFS

本次发行由思成律师事务所合伙人Benjamin Tan 以及Will Rao律师领导发行。

Sichenzia Ross Ference LLP

Sichenzia Ross Ference Kesner LLP Represents Rodman & Renshaw a unit of H.C Wainwright in a $7.4 Million Public Offering of Medical Transcript Billing, Corp.

mtbc - medical transcription billing corp. logo

Press Release – New York, NY – June 23, 2017 – Sichenzia Ross Ference Kesner LLP announced today that it has represented Rodman & Renshaw, a unit of H.C. Wainwright, as Exclusive Placement Agent and Boenning & Scattergood, Inc. as co-placement agent in a public offering of Series A Preferred stock for Medical Transcription Billing, Corp. (MTBC.NASDAQ). MTBC is a principal provider of proprietary, cloud-based electronic health records, practice management, and mHealth solutions.

continue reading >>

Sichenzia Ross Ference Kesner LLP Represents Rodman & Renshaw a unit of H.C Wainwright in $3.85 Million Public Offering of Innovus Pharmaceuticals, Inc.

innovus pharma

Press Release – New York, NY – March 21, 2017 – Sichenzia Ross Ference Kesner LLP announced today that it has represented Rodman & Renshaw a unit of H.C. Wainwright as Exclusive Placement Agent in the public offering of common stock and Warrants of Innovus Pharmaceuticals, Inc. (“INNV.OTC).

continue reading >>

Sichenzia Ross Ference Kesner LLP Represents Aegis Capital Corp. and Laidlaw & Company (UK) Ltd. in $4.8 Million Public Offering

functionx logo

Press Release – New York, NY – February 28, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented Aegis Capital Corp. and Laidlaw & Company (UK) Ltd. as joint book-running managers in the underwritten public offering of common stock of Function(x) Inc. (NASDAQ: FNCX).  Function(x) operates Wetpaint.com and Rant.

continue reading >>

Sichenzia Ross Ference Kesner LLP Represents Vuzix Corporation in $14.5 Million Registered Direct Offering.

vuzix view the future logo

Press Release – New York, NY – December 2, 2016 – Sichenzia Ross Ference Kesner LLP announced today that it has represented Vuzix Corporation (NASDAQ “VUZI”) in a Registered Direct public offering of 2 million registered shares of its common stock at a price of $7.25 per share for gross proceeds to Vuzix of $14,500,000. Chardan Capital Markets LLC acted as the exclusive Placement Agent for the offering. The Sichenzia Ross Ference Kesner LLP team was led by Partners Gregory Sichenzia, Thomas Rose, Marcelle Balcombe and Counsel Jeff Cahlon.

Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar, Feltl and Company and Fordham Financial Management in $8.6 Million Public Offering of Aytu Bioscience, Inc.

aytu bioscience

Press Release – New York, NY – November 2, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented Joseph Gunnar & Co. and Feltl and Company as Joint Book -Running Managers and Fordham Financial Management, Inc. as Lead Manager in a firm commitment underwritten public offering of equity securities of Aytu BioScience, Inc.

continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Network 1 Securities in $7.7 Million IPO and NASDAQ listing of ShineCo, Inc.

shineco inc

Press Release – New York, NY – September 30, 2016 – Sichenzia Ross Friedman Ference LLP announced today that it represented Network 1Financial Securities, Inc. as underwriter in a $7.7 million best efforts Initial Public Offering of 1,713,190 shares of common stock of ShineCo, Inc. (Nasdaq TYHT) at a public offering price of $4.50 per share. Monarch Bay Securities participated as a selected dealer. Shineco is a producer and distributor of Chinese herbal medicines, organic agricultural produce and other health based plant products in China. The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc Ross and Henry Nisser.

continue reading >>

Sichenzia Ross Friedman Ference LLP Represents BioPharmX Corporation in $930,000 Registered Direct Offering

biopharmx

Press Release – New York, NY – September 29, 2016 – Sichenzia Ross Friedman Ference LLP announced today that it has represented BioPharmX Corporation (NYSE. MKT “ BPMX) in a Registered Direct public offering of 1,550,000 registered shares of its common stock at a price of $.60 per share and 1,240,000 unregistered warrants to purchase common stock at an exercise price of $.75 per share for gross proceeds to BPMX of $930,000. Rodman & Renshaw a Unit of H.C. Wainwright & Co., LLC acted as the exclusive Placement Agent for the offering.  The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, Marcelle Balcombe and Counsel Jeff Cahlon.

continue reading >>

Sichenzia Ross Friedman Ference LLP Represents SITO MOBILE, Ltd. in $11.5 Million Public Offering

sito - single touch interactive

Press Release – New York, NY – September 21, 2016 – Sichenzia Ross Friedman Ference LLP announced today that it has represented SITO Mobile, Ltd. (NASDAQ “SITO”) in a firm commitment underwritten public offering of 3,066,667 shares of its common stock, including exercise of the underwriter’s overallotment option, at a public offering price of $3.75 per share, for gross proceeds to SITO of $11,500,000. Cowen & Co. Inc. acted as the sole book running managing underwriter for the offering. The offering was led by several institutional investors.  The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, Marcelle Balcombe, Counsel Jeff Cahlon and Associate Ashley Jaber.

continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Rodman & Renshaw as Exclusive Placement Agent for a $5 Million Registered Direct Offering

cel sci

Press Release – New York, NY – August 26, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Rodman & Renshaw, a unit of H.C. Wainwright& Co., LLC, as the exclusive placement agent for a registered direct offering of CEL-SCI Corporation (NYSE MKT: CVM), a pharmaceutical company that is focused on finding the best way to activate a patient’s immune response to fight cancer and infectious diseases (“CEL-SCI”).

continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Rodman & Renshaw as Exclusive Placement Agent for a $3.77 Registered Direct Offering

eyegate pharma logo

Press Release – New York, NY – July 11, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Rodman & Renshaw, a unit of H.C. Wainwright& Co., LLC, as the exclusive placement agent for a registered direct offering of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye (“EyeGate”).

continue reading >>

Partners Marc J. Ross and James M. Turner Represent Tonix Pharmaceuticals in $10 Million Public Offering of Common Stock

tonix pharmaceuticals

Press Release – New York, NY – June 23, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a developer of next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder, in an underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at a purchase price of $2.00 per share. Tonix raised $10 million in gross proceeds. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc. (NASDAQ:NHLD), acted as joint book-running managers for the offering.

The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner and associate Nazia Khan.

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Represents Joseph Gunnar in $2.1 Million Public Offering of Intellicheck Mobilisa, Inc.

intellicheck logo

Press Release – New York, NY – June 21, 2016 – Nationally recognized securities and corporate law firm, Sichenzia Ross Friedman Ference LLP, announced today that it has represented Joseph Gunnar & Co. LLC as sole book-running manager in a firm commitment underwritten public offering of shares and warrants of Intellicheck Mobilisa, Inc.

continue reading >>

Partners Richard A. Friedman and Stephen A. Cohen Represent Laidlaw & Company (UK) Ltd. and Roth Capital Partners, LLC as Joint Book Running Managers of PhaseRx, Inc.’s $18.5M IPO

phase rx

Press Release – New York, NY – May 23, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Laidlaw & Company (UK) Ltd. and Roth Capital Partners, LLC as Joint Book-Running Managers of the initial public offering of PhaseRx, Inc. (NASDAQ: PZRX).

continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Axiom Capital Management, Inc. In $1.2 Million Public Offering of iSign Solutions Inc.

isign

Press Release – New York, NY – May 19, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Axiom Capital Management, Inc. as the underwriter in a firm commitment underwritten public offering of equity securities of iSign Solutions Inc.

The offering consisted of 690,000 shares of common stock and warrants to purchase up to 345,000 shares of common stock. The common stock and warrants were offered at prices to the public of $1.74 and $0.01, respectively. The common stock and warrants trade under the symbols “ISGN” and “ISGW”, respectively. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, Richard Friedman, David Manno and associate Jeff Cahlon.

Sichenzia Ross Friedman Ference LLP Represents DelMar Pharmaceuticals, Inc. in $5.6 Million Sale of Series B Preferred Shares

delmar pharmaceuticals

 

Press Release – New York, NY – May 5, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm represented DelMar Pharmaceuticals, Inc. in connection with the sale of $5,600,000 of its Series B Preferred Shares.  DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments.

continue reading >>

Sichenzia Ross Friedman Ference LLP Represents H.C. Wainwright & Co., LLC and Joseph Gunnar & Co., LLC as Joint Book Running Managers for $6.0 Public Offering and Uplisting to Nasdaq

labstyle mydario

Press Release – New York, NY – March 8, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented H.C. Wainwright & Co., LLC and Joseph Gunnar & Co. as joint book running managers in a firm commitment underwritten public offering of equity securities of LabStyle Innovations Corp.

continue reading >>

Partner Richard Friedman Represents eMagin Corporation in $6M Registered Direct Offering

eMagin

Press Release – New York, NY – December 23, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm has represented eMagin Corporation (NYSE MKT: EMAN) (the “Company”), the leader in the development, design and manufacture of Active Matrix OLED microdisplays for high resolution imaging products, in connection with its $6,000,000 registered direct offering. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Oasmia Pharmaceutical AB on $9.5M IPO and U.S NASDAQ listing

oasmia

SRFF LLP Advises Fifth Swedish IPO on U.S. NASDAQ

October 28, 2015 – Press Release – New York, NY –Sichenzia Ross Friedman Ference LLP (“SRFF”) announced today the Firm has represented Oasmia Pharmaceutical AB (NASDAQ: OASM) (NASDAQ Stockholm: OSAM.ST), a Swedish biopharmaceutical company focused on developing innovative treatments within human and animal oncology, on the company’s U.S. underwritten public offering of American Depository Shares (ADSs) and warrants to purchase the company’s ADSs at an offering price of $4.06 per ADS. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Israeli Biotech Company Can-Fite Biopharma on $4.8M Registered Direct Offering of ADSs

can-fite biopharma

New York, NY – Press Release – October 15, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) announced today that the Firm has represented Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), an Israeli biotechnology company advancing a pipeline of proprietary small molecule drugs that addresses cancer and inflammatory diseases, on a registered direct offering with institutional investors where the Company issued 1,109,196 American Depository Shares (ADSs) at a purchase price of $4.35 per ADS. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents ContraVir Pharmaceuticals, Inc. on $15 Million Public Offering of Common Stock and Warrants

contravir

Press Release – New York, NY – October 14, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the Firm has represented ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical  company focused on the development and commercialization of targeted antiviral therapies, on an underwritten public offering of 5,000,000 shares of the Company’s common stock and warrants to purchase up to 3,000,000 shares of common stock at a combined public offering price of $3.00. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Amarantus BioScience Holdings, Inc. in $5.5M Registered Direct Offering and Private Placement

amarantus bioscience

October 1, 2015 — New York, NY – Press Release – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) is pleased to announce that the Firm has represented Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates for orphan indications and neurology in a registered direct offering where Amarantus issued $2.75 million of newly designated Series H convertible preferred stock and warrants. continue reading >>

Sichenzia Ross Friedman Ference LLP Represents Israeli Company Can-Fite BioPharma on $9.0M Public Offering of ADSs

can-fite biopharma

New York, NY – Press Release – September 22, 2015 –Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Israeli biotechnology company, Can-Fite BioPharma (NYSE: CANF)(TASE: CFBI) on a public offering with institutional investors where Can-Fite received $9 million in gross proceeds. continue reading >>

Sichenzia Ross Friedman Ference LLP Advises Underwriter Aegis Capital on U.S. Initial Public Offering of Israeli Biopharmaceutical Company

biondvax pharmaceuticals

Represents first Israeli-American collaborative transaction between affiliated law firms SRFF LLP and DTKGC & Co.

New York, NY – May 15, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) announced today that the Firm has represented the underwriter Aegis Capital Corp. on the U.S. initial public offering of BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), continue reading >>

Sichenzia Ross Friedman Ference LLP Advises Aegis Capital Corp. on $2.1 million Secondary Public Offering of Intellicheck Mobilisa, Inc.

intellicheck mobilisa

NEW YORK, April 9, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Aegis Capital Corp. as sole underwriter in a $2.1 million secondary public offering for Intellicheck Mobilisa (“IDN” NYSE MKT. The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 2,617,000 shares at an offering price of $.80 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Gregory Sichenzia and Marcelle Balcombe.

 

Media Contact:

pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP 代表 LaidLaw & Company (UK) 有限公司完成 Actinium Pharmaceuticals 公司的500 万美元注册直接发行

actinium pharmaceuticals

2015 6 18 纽约州纽约位于纽约的证券和公司律师事务所 Sichenzia Ross Friedman Ference LLP (“SRFF”) 今日宣布该事务所已经代表唯一配售代理 Laidlaw & Company (UK) 完成了 Actinium Pharmaceuticals 公司 (NYSE MKTATNM)(一家为治疗晚期癌症开发创新靶向免疫疗方法的生物制药公司)的注册直接发行。发行包括以每股2.60 美元的购买价发行的 1,923,078 股公司普通股,累计总收益约为5,000,000 美元。

Sichenzia Ross Friedman Ference LLP 团队由合伙人 Richard A. Friedman Stephen A. Cohen 领导

关于 Sichenzia Ross Friedman Ference LLP

Sichenzia Ross Friedman Ference LLP 是一家位于纽约的律师事务所,就涉证券行业的众多事务提供经验丰富的代理。他们的律师专门就私募配售、首次 (IPO) 和二次公开募股、替代性公开发售、编制 SEC 文件和在 NYSE纽约证券交易所)、NASDAQ OTC 场等主要资本股票交易所上市为客户提供建议。此外,该事务所的诉讼和仲裁律师在代表客户面对 SECFINRA 和其他监管机构处理从日常诉讼到复杂案例的业务方面非常熟练。SRFF 在欧洲也有国际附属公司,同样专门为外国发行商就美国 IPO 和公开发行提供建议。若要了解更多信息,请访问 www.srff.com 并在 twitter @srffllp 上关注 SRFF

Sichenzia Ross Friedman Ference LLP 建議 Solar3D 進行 1250 萬美元的公開發售,並在納斯達克上市

solar 3d

2015 3 6 紐約州紐約市全球通訊社Sichenzia Ross Friedman Ference LLP 於今日宣佈 公司代表 Solar3D, Inc. (NASDAQ:</154>SLTD)一家太陽能解決方案提供商和專利高效太陽能電池研發商,進行 300 萬個單位的公開發售。每個單位售價為 4.15 美元,包括一股普通股與一個認股權證,可以每股 4.15 美元的合約價購買一股普通股。此次發售由 Cowen & Company LLC 承銷,該機構是 Cowen Group 的分支機搆 (NASDAQ:COWN).

此外,Solar3D 的普通股將在納斯達克市場上進行交易,代碼為SLTD”,自 2015 3 6 日起生效。Sichenzia Ross Friedman Ference LLP 團隊由合夥人 Gregory SichenziaMarcelle Balcombe 和合夥人 Jeffrey Cahlon 領導

Sichenzia Ross Friedman Ference LLP簡介

Sichenzia Ross Friedman Ference LLP是一家從事證券和公司領域法律服務的律師事務所,可在證券行業所涉所有事務和所有一般性公司和訴訟事務中提供經驗豐富且專業的代理。SRFF 的客既有初創公司也有知名的上市公司。它們包括私立和公共企業、合夥企業、券商、銀行下屬券商、投資顧問、註冊工作人員、公共和企業客戶以及投資者、合作夥伴和其他實體。SRFF 也就涉及複雜證券法考慮事項的交易為機構投資者提供建議。SRFF 的執業範圍包括為美國客戶和世界各地客戶提供法律代理

媒體連絡人

pr@srf.law

 

Sichenzia Ross Friedman Ference LLP 作為獨家簿記管理人,代理 CollabRX 的 300 萬美元公開發售

collab rx

Sichenzia Ross Friedman Ference LLP 建議 Aegis Capital Corp. CollabRX, Inc. 進行 300 萬美元的公開發售

紐約州紐約市 2015 2 26 全球通訊社Sichenzia Ross Friedman Ference LLP是一家位於紐約的證券法律事務所,該所於今日宣佈,作為 Aegis Capital Corp. 的獨家簿記管理人,為 CollabRX, Inc. 進行300萬美元的公開發售(NASDAQ:</128>CLRX)CollabRX, Inc. 是一家雲端專業系統提供商,旨在指導醫療保健決策制定。此次發售依照有效 S-3 登記聲明補充的招股說明書,包括 2,362,205 股普通股,每股價 1.27 美元。Sichenzia Ross Friedman Ference LLP 團隊由合夥人 Gregory SichenziaMarcelle Balcombe 和合夥人 Jeff Cahlon 領導

關於 Sichenzia Ross Friedman Ference LLP

Sichenzia Ross Friedman Ference LLP 是一家企業和證券律師事務所,它提供經驗豐富的專業代表處理涉及證券行業以及所有一般企業和訴訟事務的所有事務。SRFF 的客既有初創公司也有知名的上市公司。它們包括私立和公共企業、合夥企業、券商、銀行下屬券商、投資顧問、註冊工作人員、公共和企業客戶以及投資者、合作夥伴和其他實體。SRFF 也就涉及複雜證券法考慮事項的交易為機構投資者提供建議。SRFF 的執業範圍包括為美國客戶和世界各地客戶提供法律代理

媒體聯繫人

pr@srf.law

(212)-930-9700

Sichenzia Ross Friedman Ference LLP Advises Aegis Capital Corp. as Sole Book-Running Manager on $5.52M Public Offering of CollabRX, Inc.

collab rx

NY, New York – February 25, 2015 – Global Newswire—Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Aegis Capital Corp. as the sole book-running manager in a $5,520,000 public offering for CollabRX, Inc. (NASDAQ: CLRX),  a provider of cloud-based expert systems for selecting clinical treatments. The public offering, which included a full exercise of the over- allotment option, consisted of 3,840,000 shares of CollabRX’s common stock and warrants to purchase up to an aggregate of 3,840,000 shares of the Company’s common stock at an offering price of $1.25 per common share and an exercise price of $1.56 per warrant.

The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, Marcelle Balcombe and Associate Jeffrey Cahlon.

Media Contact:
pr@srf.law
(212)-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP 代表 Laidlaw & Company (UK) Ltd. 公司進行 Actinium Pharmaceuticals, Inc. 價值 2000 萬美元的公開發售。

actinium pharmaceuticals

2015 12 12 紐約州紐約市 全球通訊社Sichenzia Ross Friedman Ference LLP是一家位於紐約、從事證券和公司領域法律服務的事務所。該事務所于今天宣佈,代表 Laidlaw & Company (UK) Ltd. 公司,擔任 Actinium Pharmaceuticals, Inc. 認購公開發售的獨家簿記管理人 (NYSE MKT:</3>ATNM)Actinium Pharmaceuticals, Inc. 是一家生物製藥公司,針對治療晚期癌症研發新型免疫療法。此次發售包括 4,444,444 股普通股票和認股權證,以4.50美元一股和認股權證的組合價,購買公司 3,333,333 股普通股票。此次公開發售所得款項總額約為 2000 萬美元

Sichenzia Ross Friedman Ference LLP律師團隊由合夥人Richard A. Friedman Stephen A. Cohen 領導

Sichenzia Ross Friedman Ference LLP簡介

Sichenzia Ross Friedman Ference LLP是一家從事證券和公司領域法律服務的律師事務所,可在證券行業所涉所有事務和所有一般性公司和訴訟事務中提供經驗豐富且專業的代理。SRFF 的客既有初創公司也有知名的上市公司。它們包括私立和公共企業、合夥企業、券商、銀行下屬券商、投資顧問、註冊工作人員、公共和企業客戶以及投資者、合作夥伴和其他實體。SRFF 也就涉及複雜證券法考慮事項的交易為機構投資者提供建議。SRFF 的執業範圍包括為美國客戶和世界各地客戶提供法律代理。要瞭解關於 SRFF 的更多資訊,請訪問 www.srff.comSRFF LinkedInTwitter@SRFFLLP.

在Trovagene Inc. 价值2300 万美元的公开发售中Sichenzia Ross Friedman Ference LLP担任法律顾问

trovagene

纽约州纽约市——2015211——美通社国际版——总部设在纽约市的Sichenzia Ross Friedman Ference LLP 一家从事证券和公司领域法律服务的律师事务所),今天宣布该律所已成为Trovagene, Inc. NASDAQ:TROV,一家从事无细胞分子诊断产品开发的公司)的法律顾问,为Trovagene, Inc. 5,111,110 股普通股承销公开发售提供法律意见。此次公开发售所得款项总额约为 2300 万美元。Trovagene 拟将此次发售所得的净收益用于其研究和开发活动、流动资金和其他一般性企业用途

Sichenzia Ross Friedman Ference LLP师团队的负责人是合伙人 Jeffrey J. Fessler Tara Guarneri-Ferrara

Sichenzia Ross Friedman Ference LLP 简介

Sichenzia Ross Friedman Ference LLP 是一家从事证券和公司领域法律服务的律师事务所,可在证券行业所涉所有事务和所有一般性公司和诉讼事务中提供经验丰富且专业的代理。SRFF 的客户涵盖从新创企业到发展成熟的上市公司的各种企业。包括私营和上市公司、合伙企业、券商、银行下属的券商、投资顾问、已注册证券从业人员、政府与公司客户和投资人、合伙企业和其他实体。SRFF 还就涉及复杂证券法情况的交易向机构投资者提供法律意见。SRFF 执业范围包括为美国客户和世界各地客户提供法律代理。想了解更多关于SRFF的信息,请浏览www.srff.comSRFF LinkedInTwitter@SRFFLLP

 

在Tonix Pharmaceuticals 价值2870 万美元的公开发售中Sichenzia Ross Friedman Ference LLP担任法律顾问

tonix pharmaceuticals

纽约州纽约市——2015210——美通社国际版——总部设在纽约市的Sichenzia Ross Friedman Ference LLP 一家从事证券和

公司领域法律服务的师事务所),今天宣布该律所已成为Tonix Pharmaceuticals Holding Corp.一家处于临床阶段的制药公司)的法律顾问,为Tonix Pharmaceuticals 4,900,000 股普通股承销公开发售(每股5.85 美元)提供法律意见。此次公开发售所得款项总额约为 2870 万美元

Tonix 拟将此次发售所得的收益用于支持进行中的用于管理纤维肌痛和创伤后应激障碍的TNX-102 SL的研发、用于支持用于治疗发作性紧张型头痛的TNX-201的研发、用于进一步开发其他拟定项目、用于流动资金和其他一般性企业用途。

Sichenzia Ross Friedman Ference LLP师团队负责人是合伙人Marc J. Ross James M. Turner 以及 Sharon Carroll

Sichenzia Ross Friedman Ference LLP简介

Sichenzia Ross Friedman Ference LLP是一家从事证券和公司领域法律服务的律师事务所,可在证券行业所涉所有事务和所有一般性公司和诉讼事务中提供经验丰富且专业的代理。 SRFF 的客户涵盖从新创企业到发展成熟的上市公司的各种企业。包括私营和上市公司、合伙企业、券商、银行下属的券商、投资顾问、已注册证券从业人员、政府与公司客户和投资人、合伙企业和其他实体。SRFF 还就涉及复杂证券法情况的交易向机构投资者提供法律意见。SRFF 执业范围包括为美国客户和世界各地客户提供法律代理。想了解更多关于SRFF的信息,请浏览www.srff.comSRFF LinkedInTwitter@SRFFLLP.

PlasmaTech Announces $14.0 M Public Offering and NASDAQ Listing

plasmatech biopharmaceuticals

New York, NY – December 24, 2014 – Press Release: New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm  represented H.C. Wainwright & Co. and Aegis Capital Corp. as underwriters in PlasmaTech Biopharmaceuticals, Inc.’s public offering of 3,500,000 shares of common stock and 3,500,000 warrants. The gross proceeds from the offering were $14,035,000 and the offering price was $4.00 per share and $.01 per warrant. The warrants have a per share exercise price of $5.00 and are exercisable immediately.  PlasmaTech common stock and warrants began trading on the NASDAQ Capital Market (effective December 19, 2014) under the symbols “PTBI” and “PTBIW” respectively.

PlasmaTech Biopharmaceuticals, Inc. is a biopharmaceutical company focused on advanced targeted treatments for critical patient care. The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Marcelle Balcombe.

Sichenzia Ross Ference LLP

 

Can-Fite Biopharma Ltd. Announces $8.0 M At-The-Market Registered Direct Offering

can-fite biopharma

Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharma Ltd. On A $8.0 M At-The-Market Registered Direct Offering

New York, NY – (Global Newswire) – 12/20/2014 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Israeli biopharmaceutical company, Can-Fite Biopharma Ltd. (TASE: CFBI; NYSE MKT: CANF) on an at-the-market registered direct offering of for gross proceeds of $8,000,000. The Sichenzia Ross Friedman Ference LLP team was led by Partner Gregory Sichenzia, Associates Gary Emmanuel and Avital Even-Shoshan. H.C. Wainwright & Co., LLC acted as the Placement Agent in the offering.

Sichenzia Ross Ference LLP

CEL-SCI Corporation Announces $6.0 Million Public Offering

cel sci

Sichenzia Ross Friedman Ference LLP Represents CEL-SCI Corporation on $6.0 Million Public Offering

New York, NY – October 29, 2014 – GLOBAL NEWSWIRE – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it has advised Laidlaw & Co. (UK) Ltd. as the Lead Underwriter in a $6 million public Public Offering of CEL-SCI Corporation (NYSE MKT: CVM), a late-stage biotechnology company focused on oncology research and drug development. The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of common stock and warrants at a combined price of $0.76 per unit. Pursuant to the offering, CEL-SCI issued one warrant to purchase common stock for every four shares sold. The warrants have an exercise price of $1.25 per unit. The Sichenzia Ross Friedman Ference LLP team was led by Partner Richard A. Friedman and Associate Stephen Cohen.

Sichenzia Ross Ference LLP

 

Sichenzia Ross Friedman Ference LLP Advises Tonix Pharmaceuticals on $7.8 Million Public Offering

tonix pharmaceuticals

NEW YORK, July 16, 2014 (GLOBE NEWSWIRE) –New York based securities law firm, Sichenzia Ross Friedman Ference LLP, acted as counsel to Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage pharmaceutical company focused on researching common disorders of the central nervous system, on a recently completed $7.8 million registered direct public offering pursuant to Tonix’s shelf registration statement. The offering consisted of 657,000 shares of common stock sold at $11.90 per share. Roth Capital Partners acted as the sole placement agent in this offering. The Sichenzia Ross Friedman Ference LLP team consisted of partners Marc J. Ross and James M. Turner and associate Sharon Carroll.

Media Contact
pr@srf.law
(212)-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Advises FreeSeas Inc. on $25.0 Million Public Offering of Preferred Stock and Warrants

freeseas

NEW YORK, June 5, 2014–New York- based securities law firm, Sichenzia Ross Friedman Ference LLP, advised FreeSeas Inc. (NASDAQ: FREE), a transporter of dry-bulk cargoes through the ownership and operation of a fleet of five Handysize and one Handymax vessels, in a recently completed $25 million registered direct public offering of Series D Convertible Preferred Stock and Series C Warrants. The securities consisted of one share of the Company’s Series D Convertible Preferred Stock and 184 Series C Warrants, exercisable for five years at an initial price of $1.42 per share. Each share of Series D Preferred Stock has a stated value of $100 and is convertible into a number of shares of common stock equal to $100 divided by $1.09. The Sichenzia Ross Friedman Ference LLP team was led by partners Marc J. Ross and James M. Turner.

Media Contact
pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Advises Sorrento Therapeutics, Inc. on $25.0 million Public Offering of Common Stock

sorrento

NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, in a $25.0 million public offering. The offering consists of 4,765,000 shares of common stock priced at $5.25 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Jeff Fessler and Marcelle Balcombe.

Media Contact
pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Company on $10 million Secondary Public Offering of Cyclacel Pharmaceuticals, Inc.

cyclacel

NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Laidlaw & Company (UK) Ltd. as sole underwriter in a $10 million secondary public offering for Cyclacel Pharmaceuticals, Inc. (“CYCC.” NASDAQ). The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 2,857,143 shares of common stock at an offering price of $3.50 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Richard Friedman and Stephen Cohen.

 

Media Contact:

pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Company on $6.72 million Secondary Public Offering of Novabay Pharmaceuticals, Inc.

novabay pharma

NEW YORK, March 25, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Laidlaw & Company (UK) Ltd. as sole underwriter in a $6.72 million secondary public offering for Novabay Pharmaceuticals, Inc. (“NBY” NYSE MKT). The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 5,600,000 shares of common stock and 18 month warrants to purchase 1,400,000 shares of common stock at combined offering price of $1.20 . The Sichenzia Ross Friedman Ference LLP team was led by partners Richard Friedman and Stephen Cohen.

 

Media Contact:

pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Advises Brean Capital LLC on $ 6.5 million Registered Direct Offering of ClearSign Combustion Corporation

clearsign

NEW YORK, March 5, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Brean Capital LLC. as sole Placement Agent in a $6.5 million registered direct offering for ClearSign Combustion Corporation (“CLIR” NASDAQ). The offering was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 812,500 shares at an offering price of $8.00 per share. The Sichenzia Ross Friedman Ference LLP team was led by partner Jay Kaplowitz and associate Stephen Cohen

Media Contact:

pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Represents Tonix Pharmaceuticals in $43.5 Million Shelf Takedown

tonix pharmaceuticals

SRFF Named-Partner, Marc J. Ross, Leads Transaction Whose Proceeds Will fund Development of Medications for the Treatment of Fibromyalgia and Post-Traumatic Stress Disorder

NEW YORK CITY – February 12, 2014Sichenzia Ross Friedman Ference LLP (SRFF), a leading corporate securities law firm headquartered in New York City, announces it represented Tonix Pharmaceuticals Holding Corp. (TNXP) in the closing of its confidentially marketed public offering, resulting in aggregate gross proceeds of approximately $43.5 million. The shelf takedown, which closed January 29, 2014, was led by SRFF named partner Marc J. Ross.

The SRFF team, which in addition to Ross as lead counsel included firm partner James M. Turner, advised Tonix in the underwritten public offering of 2,898,550 shares of the common stock at a price of $15.00 per share. Roth Capital Partners acted as the sole book-running manager for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as co-manager. Tonix granted the underwriters a 45-day option to acquire an additional 434,782 shares to cover overallotments in connection with the offering.

Tonix Pharmaceuticals develops prescription medications for disorders of the central nervous system, targeting conditions characterized by significant unmet medical needs, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. Tonix expects to use the net proceeds of the offering to support the continued development of TNX-102 SL for the treatment of fibromyalgia, to initiate clinical trials of TNX-102 SL for the treatment of post-traumatic stress disorder, and to initiate clinical trials of TNX-201 for tension-type headache.

Avista Capital Partners

Last modified: 2013-12-16T13:14:39Z

Copyright 2013 . All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

 

Media Contact:

pr@srf.law
(212) 930-9700

Sichenzia Ross Ference LLP

Medovex Corp. Announces $8.0 M IPO

medovex corp

Sichenzia Ross Friedman Ference LLP Represents Medovex Corp. in $ 8.0M Initial Public Offering

New York, NY – December 29, 2014 – Global Medovex NasdaqNewswire – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that the Firm has represented Medovex Corporation (NASDAQ: MDVXU), a producer of medical device products, in an initial public offering of 1,391,305 units. Each unit consisted of one share of common stock and one Series A Warrant at a price of $5.75 per unit. The IPO resulted in gross proceeds of $8,000,003 to the Company. The IPO was underwritten by Laidlaw & Company (UK) LTD.

The units trade on the NASDAQ Capital Markets under the symbol “MDVXU” and the common stock and warrants will trade under the symbols “MDVX” and “MDVXW”, respectively on separation.

Medovex is developing and commercializing the DenerVex® device, which is used in the treatment of conditions resulting from the degeneration of joints in the spine that cause back pain. In 2013, Medovex entered into a Co-Development Agreement with Dr. James Andrews, a renowned orthopedic surgeon who also is a director of the Company. Additionally Medovex intends to seek out acquisition opportunities through its world class Board of Directors which also includes Steve Gorlin, Major General C.A. “Lou” Hennies and Dr. Scott M. W. Haufe.

The Sichenzia Ross Friedman Ference LLP team was led by Partners Harvey Kesner, Arthur S. Marcus and Associate Marc J. Adesso.

Sichenzia Ross Ference LLP

Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Company on $20 Million Public Offering of Spherix Inc.

spherix intellectual property

NEW YORK, June 4, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Laidlaw & Company (UK) Ltd. as the sole placement agent in a $20 million public offering for Spherix, Inc. (NASDAQ: SPEX). The company offered a Series J preferred stock at a purchase price of $2.00 per share. Spherix Inc. is traded on the NASDAQ Capital Market under the trading symbol “SPEX”. The Sichenzia Ross Friedman Ference LLP team was led by partners Harvey Kesner, Richard A. Friedman and associates Tara Guarneri-Ferrara, and counsel Avital Even-Shoshan.

Media contact
pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP